Lee, Jeeyun

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine

Gastric Cancer Management and OutcomesCancer Genomics and Diagnostics

Cited by 2,223

Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer

Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine

Gastric Cancer Management and OutcomesHER2/EGFR in Cancer Research

Cited by 1,333

Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA

Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE

Cancer Genomics and DiagnosticsPrenatal Screening and Diagnostics

Cited by 695

Gastric adenocarcinoma

Ajani, J. A., Lee, J., Sano, T., Janjigian, Y. Y., Fan, D., & Song, S. (2017) · Nature Reviews Disease Primers

Gastric Cancer Management and OutcomesHelicobacter pylori-related gastroenterology studies

Cited by 594

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery

Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy

Cited by 504

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

Pietrantonio, F., Di Nicolantonio, F., Schrock, A. B., Lee, J., Tejpar, S., Sartore-Bianchi, A., Hechtman, J. F., Christiansen, J., Novara, L., Tebbutt, N., et al. (2017) · JNCI: Journal of the National Cancer Institute

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 317

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma

Pectasides, E., Stachler, M. D., Derks, S., Liu, Y., Maron, S., Islam, M., Alpert, L., Kwak, H., Kindler, H., Polite, B., et al. (2018) · Cancer Discovery

Cancer Genomics and DiagnosticsEsophageal Cancer Research and Treatment

Cited by 307

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors

Alvarez, M. J., Subramaniam, P. S., Tang, L. H., Grunn, A., Aburi, M., Rieckhof, G., Komissarova, E. V., Hagan, E. A., Bodei, L., Clemons, P. A., et al. (2018) · Nature Genetics

Neuroendocrine Tumor Research AdvancesNeuroblastoma Research and Treatments

Cited by 210

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 138

Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations

Lee, J., Lee, I., Han, B., Park, J. O., Jang, J., Park, C., & Kang, W. K. (2011) · JNCI: Journal of the National Cancer Institute

Colorectal Cancer Treatments and StudiesCancer, Lipids, and Metabolism

Cited by 103

Microfluidic high-throughput 3D cell culture

Ko, J., Park, D., Lee, J., Jung, S., Baek, K., Sung, K. E., Lee, J., & Jeon, N. L. (2024) · Nature Reviews Bioengineering

3D Printing in Biomedical ResearchMicrofluidic and Capillary Electrophoresis Applications

Cited by 88

Comprehensive pharmacogenomic characterization of gastric cancer

Sa, J. K., Hong, J. Y., Lee, I.-K., Kim, J.-S., Sim, M.-H., Kim, H. J., An, J. Y., Sohn, T. S., Lee, J. H., Bae, J. M., et al. (2020) · Genome Medicine

Gastric Cancer Management and OutcomesCancer Genomics and Diagnostics

Cited by 46

Broad Detection of Alterations Predicted to Confer Lack of Benefit from EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer

Rankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., et al. (2016) · The Oncologist

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 40

Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer

Randon, G., Intini, R., Cremolini, C., Elez, E., Overman, M. J., Lee, J., Manca, P., Bergamo, F., Pagani, F., Antista, M., et al. (2022) · European Journal of Cancer

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 24

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07

Kim, S. T., Kim, S. Y., Lee, J., Yun, S. H., Kim, H. C., Lee, W. Y., Kim, T. W., Hong, Y. S., Lim, S.-B., Baek, J. Y., et al. (2022) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 21